TY - JOUR A1 - Walther, Kay-Arne A1 - Gonzales, José Roberto A1 - Gröger, Sabine A1 - Ehmke, Benjamin A1 - Kaner, Dogan A1 - Lorenz, Katrin A1 - Eickholz, Peter A1 - Kocher, Thomas A1 - Kim, Ti-Sun A1 - Schlagenhauf, Ulrich A1 - Koch, Raphael A1 - Meyle, Jörg T1 - The role of polymorphisms at the Interleukin-1, Interleukin-4, GATA-3 and Cyclooxygenase-2 genes in non-surgical periodontal therapy JF - International Journal of Molecular Sciences N2 - Periodontitis is a multifactorial disease. The aim of this explorative study was to investigate the role of Interleukin-(IL)-1, IL-4, GATA-3 and Cyclooxygenase-(COX)-2 polymorphisms after non-surgical periodontal therapy with adjunctive systemic antibiotics (amoxicillin/metronidazole) and subsequent maintenance in a Caucasian population. Analyses were performed using blood samples from periodontitis patients of a multi-center trial (ClinicalTrials.gov NCT00707369=ABPARO-study). Polymorphisms were analyzed using quantitative real-time PCR. Clinical attachment levels (CAL), percentage of sites showing further attachment loss (PSAL) ≥1.3 mm, bleeding on probing (BOP) and plaque score were assessed. Exploratory statistical analysis was performed. A total of 209 samples were genotyped. Patients carrying heterozygous genotypes and single-nucleotide-polymorphisms (SNP) on the GATA-3-IVS4 +1468 gene locus showed less CAL loss than patients carrying wild type. Heterozygous genotypes and SNPs on the IL-1A-889, IL-1B +3954, IL-4-34, IL-4-590, GATA-3-IVS4 +1468 and COX-2-1195 gene loci did not influence CAL. In multivariate analysis, CAL was lower in patients carrying GATA-3 heterozygous genotypes and SNPs than those carrying wild-types. For the first time, effects of different genotypes were analyzed in periodontitis progression after periodontal therapy and during supportive treatment using systemic antibiotics demonstrating a slight association of GATA-3 gene locus with CAL. This result suggests that GATA-3 genotypes are a contributory but non-essential risk factor for periodontal disease progression. KW - periodontitis KW - polymorphisms KW - risk factor KW - periodontal therapy KW - antibiotics KW - GATA-3 KW - Interleukin-1 KW - Interleukin-4 KW - Cyclooxygenase-2 Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-284386 SN - 1422-0067 VL - 23 IS - 13 ER - TY - THES A1 - Hägele, Sandra Elisabeth T1 - QTc-Zeit-Verlängerung in der Therapie schizophrener Psychosen unter Berücksichtigung genetischer Varianz in NOS1AP T1 - QTc time prolongation in the treatment of patients with schizophrenic psychosis considering genetic variation in NOS1AP N2 - QTc-Zeit Verlängerungen sind aufgrund potentieller Übergänge in lebensbedrohliche Tachyarrhythmien Gegenstand vieler Arbeiten. Einer der Häufigsten Risikofaktoren ist die Einnahme von typischen bzw. atypischen Antipsychotika. Mehrere Studien belegen darüber hinaus genetische Einflüsse und zeigen, dass das homozygote Vorhandensein von rs12143842(T) und rs10494366(G) in NOS1AP einen verlängernden Einfluss auf die QTc-Zeit hat. Zudem scheinen oben genannte Polymorphismen von NOS1AP bei der Entwicklung schizophrener Psychosen eine Rolle zu spielen. In bisherigen Studien wurde immer nur getrennte Analysen hinsichtlich der genannten Risikofaktoren vorgenommen. In dieser Arbeit soll erstmals der gemeinsame Einfluss von Psychopharmaka und den zwei beschriebenen Polymorphismen von NOS1AP bei Patienten mit Schizophrenie untersucht werden. N2 - The prolongation of the QTc-Time interval is a well examined phenomenon due to the risk of suffering a life threatening tachyarrhythmia. In patients with schizophrenia, several risk factors have been identified one of which is taking antipsychotic medication. Genetic variation in NOS1AP polymorphisms rs12143845 (T) and rs10494366 (G) are also found to be significant risk factors. Furthermore, NOS1AP is associated with a higher risk of developing schizophrenic psychosis. This study aims to detect the impact on QTc prolongation in an analysis of combined risk factors in patients with schizophrenia. KW - QTc-Zeit Verlängerung KW - Schizophrenie KW - NOS1AP KW - QTc-Zeit KW - Psychopharmaka KW - Polymorphismen KW - QTc prolongation KW - schizophrenia KW - antipsychotics KW - polymorphisms KW - pharmacology Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-206248 ER - TY - JOUR A1 - Van de Kerkhof, Noortje W. A. A1 - Feenstra, Ilse A1 - van der Heijden, Frank M. M. A. A1 - de Leeuw, Nicole A1 - Pfundt, Rolph A1 - Stöber, Gerald A1 - Egger, Jos I. M. A1 - Verhoeven, Willem M. A. T1 - Copy number variants in a sample of patients with psychotic disorders: is standard screening relevant for actual clinical practice? JF - Neuropsychiatric Disease and Treatment N2 - With the introduction of new genetic techniques such as genome-wide array comparative genomic hybridization, studies on the putative genetic etiology of schizophrenia have focused on the detection of copy number variants (CNVs), ie, microdeletions and/or microduplications, that are estimated to be present in up to 3% of patients with schizophrenia. In this study, out of a sample of 100 patients with psychotic disorders, 80 were investigated by array for the presence of CNVs. The assessment of the severity of psychiatric symptoms was performed using standardized instruments and ICD-10 was applied for diagnostic classification. In three patients, a submicroscopic CNV was demonstrated, one with a loss in 1q21.1 and two with a gain in 1p13.3 and 7q11.2, respectively. The association between these or other CNVs and schizophrenia or schizophrenia-like psychoses and their clinical implications still remain equivocal. While the CNV affected genes may enhance the vulnerability for psychiatric disorders via effects on neuronal architecture, these insights have not resulted in major changes in clinical practice as yet. Therefore, genome-wide array analysis should presently be restricted to those patients in whom psychotic symptoms are paired with other signs, particularly dysmorphisms and intellectual impairment. KW - microarrays KW - spectrum disorders KW - schizophrenia KW - gene KW - psychopathology KW - polymorphisms KW - microdeletion KW - perspectives KW - association KW - environment KW - copy number variants KW - 1q21 KW - 7q11.2 KW - 1p13.3 Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-134769 VL - 8 ER -